Little is known about the relationship between plasma adrenomedullin concentration and the clinical findings in patients with Graves' disease (1, 2) .
Therefore, we measured the plasma adrenomedullin concentration in 20 patients with untreated Graves' disease [40.2±15.6 years (mean age±SD); age range, 15-71 years; 2 men and 18 women]. Patients who showed atrial fibrillation on the electrocardiogram or whose cardiothoracic ratio was over 50% on the chest radiogram were excluded from this study. The normal range of plasma adrenomedullin concentration is between 5.1 and 13.9 pmol/l. In this study, the plasma adrenomedullin concentration was 23.2±8.58 pmol/l (range, 9.1-41.4 pmol/l) in the 20 patients. Plasma adrenomedullin concentration was higher than the normal range in 18 out of the 20 patients. We then investigated the correlation of plasma adrenomedullin concentration with age, body mass index (BMI) (21.2±3.19 kg/m 2 ; range, 16.0-28.8 kg/m 2 , ultrasonographically measured thyroid weight (51.3±23.0 g; range, 25-100 g) (3), TSH-binding inhibitor immunoglobulin level (43.3±27.2%; range, 2.9-89.6%), free T3 level (14.6±4.51 pg/ml; range 4.8-more than 20 pg/ml: a concentration of more than 20 pg/ml in four patients was considered to be 20 pg/ml in the analysis), free T4 level (6.27±3.15 ng/dl; range, 2.03-12.14 ng/dl), resting pulse rate (103.3±19.2 beats per minute; range, 73-144 beats per minute), mean blood pressure (95.1±11.1 mmHg; range, 79-119 mmHg), and plasma brain natriuretic peptide concentration (40.2±34.0 pg/ml; range, less than 4 to 130 pg/ml: a concentration less than 4 pg/ml in one patient was considered to be 4 pg/ml in the analysis) using Spearman's rank correlation coefficient. As shown in Fig. 1 , a significant correlation was observed between plasma adrenomedullin concentration and free T3 level, free T4 level, thyroid weight, and resting pulse rate. However, no significant correlation was observed between plasma adrenomedullin concentration and the other parameters (p>0.05). Moreover, the result of the stepwise multiple regression analysis with forward selection was as follows: plasma adrenomedullin concentration (pmol/l)= 2.079+0.172× thyroid weight (g) +0.838× free T3 level (pg/ml) (R 2 =0.615, p=0.0001). Plasma adrenomedullin concentration was also measured in eight patients who became euthyroid 3-6 months after receiving an antithyroid drug (n=7) or after 131 I treatment (n=1). The plasma adrenomedullin concentration before the treatment in these eight patients was 22.6±9.94 pmol/l and it decreased to 10.7±2.05 pmol/l after the treatment. This difference was significant (Wilcoxon's signed-rank test, p=0.0173).
Adrenomedullin has a potent and long-lasting vasodilatory activity. Its concentration was high in 90% of the patients with untreated Graves' disease, suggesting that an increased adrenomedullin concentration plays a role in reducing the peripheral vascular resistance observed in patients with Graves' disease (2). Moreover, there was a positive correlation between plasma adrenomedullin concentration and free thyroid hormone level. Furthermore, plasma adrenomedullin concentration decreased when the patients became euthyroid. These results indicate that the production and/or degradation of adrenomedullin may be directly (4, 5) and/or indirectly influenced by the thyroid hormones secreted in humans. In contrast to the report of Taniyama et al (1), there was a positive correlation between plasma adrenomedullin concentration and the resting heart rate, indicating that the cardiac effect of the thyroid hormones is caused partly by the reduced peripheral vascular resistance due to adrenomedullin.
Based on the findings of the present study, we do not support the results of Diekman et al (2), who reported that the plasma adrenomedullin concentration did not differ between patients with hyperthyroidism and hypothyroidism, suggesting that the plasma adrenomedullin concentration is not affected by circulating thyroid hormones. In that study, the plasma adrenomedullin concentration did not change after treatment of hypothyroidism with l-T4, but it decreased after treatment of hyperthyroidism with an antithyroid drug in combination with l-T4. However, they did not mention the reason why the plasma adrenomedullin concentration decreased in patients with hyperthyroidism after the treatment. In 1998, Murakami et al (4) reported that plasma adrenomedullin concentration was significantly lower in hypothyroid rats and higher in hyperthyroid rats compared with control rats.
It is considered that thyroid weight itself does not influence the human circulatory system. However, the stepwise multiple regression analysis showed that thyroid weight and free T3 level were two independent determinants of plasma adrenomedullin concentration in patients with Graves' disease. Thus, the present study also indicates that weighing the thyroid gland may provide useful information on various aspects of clinical thyroidology. 
